Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takeda Pharmaceutical Company ( (TAK) ) has issued an announcement.
On June 25, 2025, Takeda Pharmaceutical Company held its 149th Ordinary General Meeting of Shareholders, where several key resolutions were passed. The meeting approved a year-end dividend of 98 JPY per share, the election of ten directors, and the payment of bonuses to directors, reflecting strong shareholder support for the company’s strategic direction. These decisions are expected to reinforce Takeda’s governance structure and financial strategy, potentially strengthening its market position and enhancing shareholder value.
The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.
Spark’s Take on TAK Stock
According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.
Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.
To see Spark’s full report on TAK stock, click here.
More about Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader based in Tokyo, Japan. The company focuses on delivering life-transforming treatments, with a strong commitment to research and development in areas such as oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.
Average Trading Volume: 2,272,848
Technical Sentiment Signal: Buy
Current Market Cap: $48.13B
Find detailed analytics on TAK stock on TipRanks’ Stock Analysis page.